Paul Rennert
@pdrworld.bsky.social
Biotech exec, pro drug developer. Amateur everything else: COOKING, ferments, preserving, charcuterie, fishing, gardening, weightlifting, BIRDER, photography, physics, literature, writer, history, DAD
birders---> maybe a good winter coming for northern finches and friends
finchnetwork.org/winter-finch...
#birders #birding #massbird
finchnetwork.org/winter-finch...
#birders #birding #massbird
Winter Finch Forecast 2025-2026 - FINCH RESEARCH NETWORK
By Tyler Hoar Featured Post Photo: ©David Turgeon GENERAL FORECAST It looks to be a flight year for many species in Eastern Canada. With mostly very poor crops in the boreal forest from central Quebec...
finchnetwork.org
September 30, 2025 at 11:27 AM
birders---> maybe a good winter coming for northern finches and friends
finchnetwork.org/winter-finch...
#birders #birding #massbird
finchnetwork.org/winter-finch...
#birders #birding #massbird
lovely writeup at BBC #Seurat bbc.com/culture/arti...
'As urgent and relevant today as it ever was': The radical manifesto hidden in Georges Seurat's 1884 masterpiece
Georges Seurat's once-mocked painting Bathers at Asnières is both an "exquisite distillation of the very essence of summer" and "a modern wonder in the art of seeing".
bbc.com
August 15, 2025 at 6:05 PM
lovely writeup at BBC #Seurat bbc.com/culture/arti...
A very interesting bispecific ADC highlighted today by
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
Bristol's third pivotal iza-bren study
oncologypipeline.com
August 15, 2025 at 6:03 PM
A very interesting bispecific ADC highlighted today by
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
@JacobPlieth on X
-
oncologypipeline.com/apexonco/bri...
while this discussion is focused on lung cancer, the first approval for iza-bren likely in nasopharyngeal carcinoma $BMY #SystImmune
odd dynamic between clean energy needs and protecting ocean/avian ecosystems
hard to choose a side? yep...
chng.it/ThgpyJY2Pw
hard to choose a side? yep...
chng.it/ThgpyJY2Pw
This campaign needs you now
Ban the over-use of single use plastics.
chng.it
July 25, 2025 at 4:27 PM
odd dynamic between clean energy needs and protecting ocean/avian ecosystems
hard to choose a side? yep...
chng.it/ThgpyJY2Pw
hard to choose a side? yep...
chng.it/ThgpyJY2Pw
for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...
July 22, 2025 at 11:54 AM
for #biotech and advanced therapeutics followers, a cool paper here: doi.org/10.1016/j.me...
Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma
Chimeric antigen receptor (CAR) T-cell therapy has shown impressive efficacy in treating
relapsed or refractory multiple myeloma. Nonetheless, its availability is substantially
restricted by complex m...
www.thelancet.com
July 8, 2025 at 12:53 PM
Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
July 8, 2025 at 12:13 PM
Concentra goes shopping again, adds CARGO to its market basket
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
finance.yahoo.com/news/cargo-t...
Cargo, IGM, Elevation Oncology, Kronos Bio, Allakos
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
July 7, 2025 at 11:39 AM
HER3 activation and overexpression in cancers makes this antigen an attractive target for antibody therapeutics ---> a rapidly expanding drug development landscape has emerged sugarconebiotech.com/insights
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
July 6, 2025 at 2:22 PM
In the inflammatory #fibrosis space, $PLRX stopped development of bexotegrast avb6/avb1 inhibitor for the treatment of IPF "due to worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause mortality" (27 June 2025). Yikes.
tgif.
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'
15. The Wheel -} Wharf Rat - Grateful Dead - 5/7/77 Boston Garden, Boston, MA - U31DoD 2012 Edition
YouTube video by NuttyRiv3r
www.youtube.com
June 20, 2025 at 11:59 PM
tgif.
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'
goosebumps at this Wharf Rat, starts @ 10:28
www.youtube.com/watch?v=I1FV...
the wheel is nice too, but man... 'i got up and wandered'
quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue
www.sugarconebiotech.com/insights/goo...
www.sugarconebiotech.com/insights/goo...
Good things come in 3s — SugarCone Biotech
DLL3, B7H3 and Her3 are compelling tumor antigens to target with cancer therapeutics. They have interesting patterns of expression in different cancer indications; thus, diverse therapies for attackin...
www.sugarconebiotech.com
June 20, 2025 at 12:31 PM
quick series on emerging #cancer targets w updates post #ASCO25 from the biopharma/venture capital consultancy experts - sugarconebiotech.com #biotech #bioblue
www.sugarconebiotech.com/insights/goo...
www.sugarconebiotech.com/insights/goo...
A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky
www.astrazeneca.com/media-centre...
www.astrazeneca.com/media-centre...
Acquisition of EsoBiotec completed
www.astrazeneca.com
May 20, 2025 at 2:12 PM
A quick note of thanks to Esobiotec's management and Board of Directors as the AstraZeneca acquisition is now completed. Our job is done with this happy exit, and so the current Board, myself included, disperses. Its a bittersweet moment for me. #biotech #biosky
www.astrazeneca.com/media-centre...
www.astrazeneca.com/media-centre...
ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...
Novel bispecific antibodies – Part 2 – immunology, asthma and atopic dermatitis — SugarCone Biotech
In 1986 - nearly 40 years ago - the first antibody therapy was FDA-approved: muromonab-CD3 (Orthoclone OKT3®), a murine monoclonal antibody targeting human CD3 expressed on T cells. This therapy was u...
sugarconebiotech.com
April 17, 2025 at 5:17 PM
ln early March I talked about the bispecific antibody landscape in IAI, specifically for atopic dermatitis and asthma. This remains a red hot area #biosky #biotech ... and we've added analysts to keep up the pace. See sugarconebiotech.com/insights/nov...
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 9, 2025 at 11:11 AM
Reposted by Paul Rennert
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 8, 2025 at 8:18 PM
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
April 8, 2025 at 8:18 PM
Here we look at the state of In Vivo CAR T cell technology and companies, post Astra Zeneca's billion dollar Esobiotec acquisition and amid biotech's financing woes: www.sugarconebiotech.com/insights
Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms
Beigene news via #ApexOnco
www.oncologypipeline.com/apexonco/bei...
Beigene news via #ApexOnco
www.oncologypipeline.com/apexonco/bei...
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
www.oncologypipeline.com
April 3, 2025 at 2:05 PM
Bye-Bei TIGIT - a lesson in the dangers of mediocre science butting up against the challenges of complex ligand/receptor interactions, FcReceptor biology, and cancer resistance mechanisms
Beigene news via #ApexOnco
www.oncologypipeline.com/apexonco/bei...
Beigene news via #ApexOnco
www.oncologypipeline.com/apexonco/bei...
omg it worked! #bispecifics #oncology #Tcells
www.sugarconebiotech.com/insights/ale... cc www.aletabio.com
www.sugarconebiotech.com/insights/ale... cc www.aletabio.com
Aleta’s Novel T Cell Engagers — SugarCone Biotech
Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...
www.sugarconebiotech.com
March 28, 2025 at 1:06 PM
omg it worked! #bispecifics #oncology #Tcells
www.sugarconebiotech.com/insights/ale... cc www.aletabio.com
www.sugarconebiotech.com/insights/ale... cc www.aletabio.com
T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ...
www.aletabio.com/blog-1-1/ale...
@BioAleta
www.aletabio.com/blog-1-1/ale...
@BioAleta
Aleta’s Novel T Cell Engagers — Aleta Biotherapeutics
By Paul Rennert Aleta’s CSO and Co-Founder Paul Rennert talks about the company’s recent announcement that their scientists created, characterized, and validated novel classes of Immune Cell Engager...
www.aletabio.com
March 25, 2025 at 1:41 PM
T CELL ENGAGER PROTEINS WITH BUILT IN COSTIMULATORY DOMAINS THAT TURN TUMOR CELLS INTO IMMUNE CELL MIMICS AND TRIGGER IMMUNE SYNAPSE SIGNALING ...
www.aletabio.com/blog-1-1/ale...
@BioAleta
www.aletabio.com/blog-1-1/ale...
@BioAleta
Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ...
www.sugarconebiotech.com/insights/ale...
proprietary technology that works just as well with CAR T engager proteins
#aletabio #bispecifics #CARTcells
www.sugarconebiotech.com/insights/ale...
proprietary technology that works just as well with CAR T engager proteins
#aletabio #bispecifics #CARTcells
Aleta’s Novel T Cell Engagers — SugarCone Biotech
Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (...
www.sugarconebiotech.com
March 24, 2025 at 9:51 PM
Our most potent T cell bispecifics leverage natural T cell immunology to kill cancer cells ...
www.sugarconebiotech.com/insights/ale...
proprietary technology that works just as well with CAR T engager proteins
#aletabio #bispecifics #CARTcells
www.sugarconebiotech.com/insights/ale...
proprietary technology that works just as well with CAR T engager proteins
#aletabio #bispecifics #CARTcells
March 18, 2025 at 9:32 PM